Nationwide Blood Pressure Medication Recall: Macleods Pharma Pulls Thousands of Bottles After FDA Quality Failure
The FDA has classified a nationwide recall of Macleods blood pressure medication after tablets failed dissolution testing. Check affected lot numbers, NDC codes, and important safety information.
Nationwide Recall Affects Thousands of Blood Pressure Medication Bottles
Thousands of bottles of a prescription blood pressure medication are being recalled across the United States after failing to meet federal quality standards. The recall involves a combination drug manufactured for Macleods Pharma USA, which contains three active ingredients commonly prescribed to manage high blood pressure.
According to the U.S. Food and Drug Administration (FDA), the affected tablets did not meet required dissolution specifications during quality testing. Dissolution testing measures how effectively a tablet breaks down under controlled laboratory conditions, an important factor in ensuring that medication performs as expected.
The company initiated the voluntary recall on October 7, 2026. The FDA subsequently classified the action as a Class II recall on October 26, 2026.
A total of 3,744 bottles are included in the recall. Consumers who take this medication should check their prescription packaging and contact their pharmacist or healthcare provider to determine whether their supply is affected.
Which Blood Pressure Medication Is Being Recalled?
The recall concerns olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets in the following strength:
- Olmesartan medoxomil: 40 mg
- Amlodipine: 10 mg
- Hydrochlorothiazide: 12.5 mg
These three medications work through different mechanisms to help lower blood pressure. Combining them into one prescription tablet can help patients manage hypertension as part of a treatment plan prescribed by their healthcare professional.
The recalled medication was manufactured by Macleods Pharmaceuticals Ltd. in Daman, India, for Macleods Pharma USA, headquartered in Princeton, New Jersey.
According to the FDA recall information, the affected products were distributed nationwide throughout the United States.
Check These Lot Numbers and Product Codes
Patients and caregivers should carefully examine the labels on their prescription bottles. The recall applies to two specific packaging sizes and their corresponding lot numbers.
Affected 30-tablet bottles:
- Lot number: 12251163A
- National Drug Code (NDC): 33342-246-07
- Package size: 30 tablets
- Expiration date: May 31, 2027
- Quantity recalled: 3,528 bottles
Affected 90-tablet bottles:
- Lot number: 12251163B
- National Drug Code (NDC): 33342-246-10
- Package size: 90 tablets
- Expiration date: May 31, 2027
- Quantity recalled: 216 bottles
The total number of recalled bottles is 3,744.
It is important to note that the recall does not automatically apply to every medication containing olmesartan, amlodipine, or hydrochlorothiazide. It specifically concerns the identified product, strength, lot numbers, and packaging information.
Patients should not assume their medication is affected simply because it contains one or more of these ingredients.
Why Did the FDA Classify the Recall as Class II?
The FDA identified a failure to meet dissolution standards as the reason for the recall.
Dissolution testing is an essential part of pharmaceutical quality control. It evaluates how a tablet releases its active ingredients when exposed to a controlled liquid environment designed to simulate conditions inside the body.
When a medication fails this testing, there may be concerns about whether it will dissolve as intended. This could affect the consistency and reliability of the drug's performance.
The FDA assigned the recall a Class II classification.
A Class II recall generally means that exposure to or use of the affected product could cause temporary health consequences or medically reversible problems. However, the probability of serious adverse health consequences is considered remote.
This classification does not mean that every patient who has taken the medication will experience a health problem. It indicates that the product has a quality issue that requires attention.
What Should Patients Do If They Have the Recalled Medication?
Anyone who believes they have one of the affected bottles should take the recall seriously and verify the product details.
Here are some important steps:
1. Check your prescription bottle
Look for the medication name, dosage strength, lot number, and NDC. Compare these details with the information listed in the FDA recall notice.
2. Contact your pharmacist
A pharmacist can help determine whether your prescription belongs to an affected lot and explain the appropriate next steps.
3. Speak with your healthcare provider
Patients should discuss their treatment options with their doctor if their medication is included in the recall. A healthcare professional can recommend an appropriate replacement or alternative treatment if necessary.
4. Follow the recall instructions
Contact the pharmacy or manufacturer for information about returning or replacing affected medication. Follow the instructions provided for the specific recall.
5. Avoid making medication changes independently
Blood pressure medication plays an important role in preventing complications associated with uncontrolled hypertension. Patients should not abruptly discontinue prescribed treatment without obtaining professional medical guidance.
Why Blood Pressure Treatment Matters
High blood pressure, also known as hypertension, is a major risk factor for cardiovascular disease. When blood pressure remains elevated over time, it places additional strain on the heart and blood vessels.
If left unmanaged, hypertension can increase the risk of serious complications, including heart attacks, strokes, and kidney problems.
The recalled combination medication contains three active ingredients:
- Olmesartan medoxomil: An angiotensin II receptor blocker that helps relax blood vessels.
- Amlodipine: A calcium channel blocker that helps widen blood vessels and improve blood flow.
- Hydrochlorothiazide: A diuretic that helps the body remove excess salt and water.
Together, these medications help reduce blood pressure and lower the risk of cardiovascular complications.
This is why patients should seek professional advice before changing their treatment following a medication recall.
Other Macleods Pharmaceutical Recalls Reported in 2026
The latest blood pressure medication recall follows other product recalls involving Macleods Pharmaceuticals this year.
In February 2026, Macleods Pharma USA recalled 1,315 bottles of levothyroxine sodium, a prescription medication used to treat an underactive thyroid. The FDA identified a failure to meet required strength specifications.
In August 2026, Macleods Pharmaceuticals also recalled 22,032 bottles of olanzapine 5 mg tablets. The medication is prescribed for certain mental health conditions, including schizophrenia and bipolar I disorder. The recall followed testing that identified impurities exceeding permitted limits.
These separate incidents involved different medications and quality concerns. They should not be confused with the current blood pressure medication recall.
Another Blood Pressure Drug Recall Reported in October
The Macleods recall is not the only blood pressure medication recall reported in October 2026.
Viatris also initiated a recall involving 21,620 bottles of telmisartan and amlodipine tablets distributed nationwide.
The affected products included five lots of 40 mg/5 mg tablets packaged in bottles containing 30 tablets.
According to the FDA information, the concern was that the affected tablets could contain more telmisartan than permitted. The FDA classified this separate recall as Class III, a category generally associated with a low likelihood of adverse health consequences.
Although both recalls involve blood pressure medications, they concern different products, manufacturers, and quality issues.
Final Thoughts
The nationwide recall of 3,744 bottles of Macleods blood pressure medication highlights the importance of pharmaceutical quality testing and medication safety monitoring.
The FDA's Class II classification indicates that the identified quality issue could cause temporary or medically reversible health consequences, although serious harm is considered unlikely.
Patients taking olmesartan medoxomil, amlodipine, and hydrochlorothiazide should check their prescription labels for the affected lot numbers and NDC codes. Anyone with a potentially affected product should contact their pharmacist or healthcare provider for instructions.
Staying informed about medication recalls can help patients make safer decisions while maintaining consistent treatment for high blood pressure.
Sources
- U.S. Food and Drug Administration (FDA), Enforcement Report, October 26, 2026.
- Recall information: Macleods Pharma USA, Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets, Recall Number D-0077-2027, Event ID 100113.
Medical Disclaimer
This article is intended for general informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Medication recalls and safety information may change as regulatory agencies release updates. Patients should consult a qualified healthcare professional or pharmacist regarding recalled medications and any changes to prescribed treatment. Do not stop or modify blood pressure medication without professional medical guidance. Always refer to official FDA announcements for the latest recall information.